drugset / Trial / NCT03923842
Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours
Phase 2
Unknown
45 enrolled
Gruppo Oncologico del Nord-Ovest
Mario Negri Institute for Pharmacological Research · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of the present investigation is to test of the modulation obtained with denosumab as "priming" therapy before the start of chemotherapy and as concurrent therapy in a population of first line NPC recurrent/metastatic patients
Timeline
- Start
- 2019-06-30
- Primary completion
- 2021-09-30
- Completion
- 2022-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Denosumab | Monoclonal antibody | 120 mg | Subcutaneous |
| Comparator | Gemcitabine | Small molecule | 1250 mg/m2 | — |